Under the terms of the license agreement with Cancer Research Technology (CRT), ValiRx has a period of 12 months in which to complete the pre-clinical regulatory development of VAL201 including toxicology, prior to exercising its option to acquire exclusive worldwide rights to the compound as an anti-cancer agent and subsequently progress to clinical trials.
Satu Vainikka, CEO of ValiRx, said: “This agreement further extends our relationship with CRT and expands our portfolio of late pre-clinical compounds. If successful, VAL 201 could offer the potential for novel treatment approaches to prostate cancer treatment where there is currently unmet need.”